Eli Lilly has filed six new lawsuits against U.S. entities selling unapproved retatrutide, an investigational drug still in Phase 3 trials for obesity and diabetes. The company warns that black-market retatrutide is unsafe and illegal, urging regulators, social media platforms, and payment processors to help stop its distribution. Lilly has also reported thousands of illegal listings worldwide and called for coordinated global enforcement to protect patients from these dangerous products. This legal action highlights the growing concern over unregulated drug sales posing health risks to consumers.
Eli Lilly and NVIDIA both reported strong quarterly results, with Lilly growing 47.7% driven by obesity drugs Mounjaro and Zepbound, and NVIDIA soaring 105.8% on AI data center demand. Lilly focuses on expanding its pharmaceutical portfolio and manuf...
The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical ...
Novartis' failed cholesterol drug trial for pelacarsen caused a sharp 14% drop in its stock and dragged down the entire Lp(a) drug class, hitting Amgen hardest with a 10% decline despite Amgen's positive Phase 3 lung cancer trial results announced th...
Novartis announced that its drug pelacarsen, designed to lower the harmful cholesterol Lp(a), failed to significantly reduce cardiovascular events in a late-stage trial. This setback raises doubts about the effectiveness of targeting Lp(a) to prevent...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four key metrics. Since its inception, it has delivered an average return of 14.89%, marginally beating SCHD's 14....
